 |
 |
* Agreement with AstraZeneca for Cubist to promote MERREM I.V. in the US. MERREM is a registered trademark of the AstraZeneca group of companies.
| ** | Pursuant to exclusive collaboration agreement with Dyax Corp. |
| *** | Pursuant to exclusive collaboration agreement with Alnylam Pharmaceuticals |
To support multiple discovery IND-generating programs in antibacterials, Cubist has significant internal capabilities in biology, medicinal chemistry, chemical development, drug metabolism, and toxicology. We also support other acute care therapeutic areas from idea generation for new approaches through support for marketed products, such as CUBICIN.
Read more »